keyword
MENU ▼
Read by QxMD icon Read
search

estrogen aggression

keyword
https://www.readbyqxmd.com/read/29781317/combination-therapies-for-the-treatment-of-her2-positive-breast-cancer-current-and-future-prospects
#1
Mariana Brandão, Noam F Pondé, Francesca Poggio, Nuria Kotecki, Mauren Salis, Matteo Lambertini, Evandro de Azambuja
HER2-positive disease is an aggressive subtype of breast cancer that has been revolutionized by anti-HER2 directed therapies. Multiple drugs have been developed and are currently in clinical use, including trastuzumab, lapatinib, pertuzumab, T-DM1 and neratinib, alone or combined in "dual HER2-blockade" regimens. Areas covered: A comprehensive literature review was performed regarding the current state and the future of combination regimens containing anti-HER2 agents, focusing on their efficacy, toxicity and cost-effectiveness...
May 21, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29780747/precision-medicine-in-hormone-receptor-positive-breast-cancer
#2
REVIEW
Azadeh Nasrazadani, Roby A Thomas, Steffi Oesterreich, Adrian V Lee
In recent decades, breast cancer has become largely manageable due to successes with hormone receptor targeting. Hormone receptor-positive tumors have favorable outcomes in comparison to estrogen receptor (ESR1, ER)/progesterone receptor-negative tumors given the targetable nature of these tumors, as well as their inherently less aggressive character. Nonetheless, treatment resistance is frequently encountered due to a variety of mechanisms, including ESR1 mutations and loss of ER expression. A new era of precision medicine utilizes a range of methodologies to allow real-time analysis of individual genomic signatures in metastases and liquid biopsies with the goal of finding clinically actionable targets...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29769550/prenatal-alcohol-exposure-increases-the-susceptibility-to-develop-aggressive-prolactinomas-in-the-pituitary-gland
#3
Shaima Jabbar, Kenneth Reuhl, Dipak K Sarkar
Excess alcohol use is known to promote development of aggressive tumors in various tissues in human patients, but the cause of alcohol promotion of tumor aggressiveness is not clearly understood. We used an animals model of fetal alcohol exposure that is known to promote tumor development and determined if alcohol programs the pituitary to acquire aggressive prolactin-secreting tumors. Our results show that pituitaries of fetal alcohol-exposed rats produced increased levels of intra-pituitary aromatase protein and plasma estrogen, enhanced pituitary tissue growth, and upon estrogen challenge developed prolactin-secreting tumors (prolactinomas) that were hemorrhagic and often penetrated into the surrounding tissue...
May 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29765514/wnt5a-induced-cell-migration-is-associated-with-the-aggressiveness-of-estrogen-receptor-positive-breast-cancer
#4
Yoshie Kobayashi, Takayuki Kadoya, Ai Amioka, Hideaki Hanaki, Shinsuke Sasada, Norio Masumoto, Hideki Yamamoto, Koji Arihiro, Akira Kikuchi, Morihito Okada
Elevated expression of Wnt5a is associated with malignancy, cell invasion, and metastasis. The role of Wnt5a expression in breast cancer remains elusive. We investigated the significance of Wnt5a expression in breast cancer. The relationship between Wnt5a expression and clinicopathologic factors was assessed in invasive breast cancer ( n = 178) resected at Hiroshima University Hospital between January 2011 and February 2014. Wnt5a was expressed in 69 of 178 cases (39%) of invasive breast cancer and correlated strongly with estrogen receptor (ER) expression ( P < 0...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29761323/effect-of-glucocorticoid-use-on-survival-in-patients-with-stage-i-iii-breast-cancer
#5
Ching-Hung Lin, Po-Ya Chuang, San-Lin You, Chun-Ju Chiang, Chiun-Sheng Huang, Ming-Yang Wang, Ming Chao, Yen-Shen Lu, Ann-Lii Cheng, Chao-Hsiun Tang
PURPOSE: Glucocorticoids (GCs) are commonly used in breast cancer patients to ameliorate emesis induced by chemotherapy. Some preclinical studies have suggested that systemic GCs might promote survival of estrogen receptor (ER)-negative breast cancer cells. This study aims to clarify their clinical effect on patient survival. METHODS: A total of 18,596 women with newly diagnosed stage I-III breast cancer in 2002-2006 were identified from the Taiwan Cancer Database and drug treatment was examined from the Taiwan National Health Insurance Claims Database...
May 14, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29753961/the-role-of-parp-inhibition-in-triple-negative-breast-cancer-unraveling-the-wide-spectrum-of-synthetic-lethality
#6
REVIEW
Marios Papadimitriou, Giannis Mountzios, Christos A Papadimitriou
Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers and is characterized by a lack of immunohistochemical expression of estrogen receptors (ER), progesterone receptors (PR) and HER2. TNBC is associated with poor long-term outcomes compared with other breast cancer subtypes. Many of these tumors are also basal-like cancers which are characterized by an aggressive biological behavior with a distant recurrence peak observed early at 3 years following diagnosis. Furthermore, metastatic TNBC bears a dismal prognosis with an average survival of 12 months...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29734758/the-prevalence-of-cd146-expression-in-breast-cancer-subtypes-and-its-relation-to-outcome
#7
Ingeborg E de Kruijff, Anna M Timmermans, Michael A den Bakker, Anita M A C Trapman-Jansen, Renée Foekens, Marion E Meijer-Van Gelder, Esther Oomen-de Hoop, Marcel Smid, Antoinette Hollestelle, Carolien H M van Deurzen, John A Foekens, John W M Martens, Stefan Sleijfer
CD146, involved in epithelial-to-mesenchymal transition (EMT), might affect cancer aggressiveness. We here investigated the prevalence of CD146 expression in breast cancer subtypes, its relation to prognosis, the relation between CD146 and EMT and the outcome to tamoxifen. Primary breast cancer tissues from 1342 patients were available for this retrospective study and immunohistochemically stained for CD146. For survival analyses, pure prognosis was studied by only including lymph-node negative patients who did not receive (neo)adjuvant systemic treatment ( n = 551)...
May 5, 2018: Cancers
https://www.readbyqxmd.com/read/29727200/tamoxifen-never-ceases-to-amaze-new-findings-on-non-estrogen-receptor-molecular-targets-and-mediated-effects
#8
Tatiana Anatolievna Bogush, Boris Borisovich Polezhaev, Ivan Andreevich Mamichev, Elena Alexandrovna Bogush, Boris Evseevich Polotsky, Sergei Alexeevich Tjulandin, Andrey Borisovich Ryabov
Tamoxifen is a first targeted drug that continues to be the gold standard in treatment of estrogen receptor positive breast cancer for almost 50 years. The current review is an update of the paper published in 2012. We provide the new data on the tamoxifen targets that are the key points of signaling cascades activating cellular proliferation, which determines aggressiveness of disease and chemotherapy resistance or sensitivity. Some inspiring clinical cases dealing with tamoxifen efficiency in treatment of different tumors are discussed...
May 4, 2018: Cancer Investigation
https://www.readbyqxmd.com/read/29714680/intratumoral-spatial-heterogeneity-at-perfusion-mr-imaging-predicts-recurrence-free-survival-in-locally-advanced-breast-cancer-treated-with-neoadjuvant-chemotherapy
#9
Jia Wu, Guohong Cao, Xiaoli Sun, Juheon Lee, Daniel L Rubin, Sandy Napel, Allison W Kurian, Bruce L Daniel, Ruijiang Li
Purpose To characterize intratumoral spatial heterogeneity at perfusion magnetic resonance (MR) imaging and investigate intratumoral heterogeneity as a predictor of recurrence-free survival (RFS) in breast cancer. Materials and Methods In this retrospective study, a discovery cohort (n = 60) and a multicenter validation cohort (n = 186) were analyzed. Each tumor was divided into multiple spatially segregated, phenotypically consistent subregions on the basis of perfusion MR imaging parameters. The authors first defined a multiregional spatial interaction (MSI) matrix and then, based on this matrix, calculated 22 image features...
April 27, 2018: Radiology
https://www.readbyqxmd.com/read/29699761/prospective-evaluation-of-self-reported-aggression-in-transgender-persons
#10
Justine Defreyne, Guy T'Sjoen, Walter Pierre Bouman, Nicola Brewin, Jon Arcelus
BACKGROUND: Although research on the relation between testosterone and aggression in humans is inconclusive, guidelines (including the World Professional Association for Transgender Health Standards of Care, edition 7) have warned for an increase in aggression in transgender men taking testosterone treatment. AIMS: To investigate the association between levels of testosterone and aggression in treatment-seeking transgender people and explore the role of mental health psychopathology (anxiety and depressive symptoms) and social support in aggression in this population...
May 2018: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29698439/tnf-differentially-regulates-ganglioside-biosynthesis-and-expression-in-breast-cancer-cell-lines
#11
Justine H Dewald, Sumeyye Cavdarli, Agata Steenackers, Clément P Delannoy, Marlène Mortuaire, Corentin Spriet, Maxence Noël, Sophie Groux-Degroote, Philippe Delannoy
Gangliosides are glycosphingolipids concentrated in glycolipid-enriched membrane microdomains. Mainly restricted to the nervous system in healthy adult, complex gangliosides such as GD3 and GD2 have been shown to be involved in aggressiveness and metastasis of neuro-ectoderm derived tumors such as melanoma and neuroblastoma. GD3 synthase (GD3S), the key enzyme that controls the biosynthesis of complex gangliosides, was shown to be over-expressed in Estrogen Receptor (ER)-negative breast cancer tumors, and associated with a decreased overall survival of patients...
2018: PloS One
https://www.readbyqxmd.com/read/29678787/cd44-directed-nanomicellar-payload-delivery-platform-for-selective-anticancer-effect-and-tumor-specific-imaging-of-triple-negative-breast-cancer
#12
Zhaoxian Wang, Samaresh Sau, Hashem O Alsaab, Arun K Iyer
Triple negative breast cancer (TNBC) is a highly aggressive tumor subtype, lacking estrogen, progesterone and human epidermal growth factor-2 (HER-2) receptors. Thus, early detection and targeted therapy of TNBC is an urgent need. Herein, we have developed a CD44 targeting Hyaluronic Acid (HA) decorated biocompatible oligomer, containing FDA approved vitamin E TPGS and Styrene Maleic Anhydride (SMA) (HA-SMA-TPGS) for targeting TNBC. The self-assembling HA-SMA-TPGS was encapsulated with poorly water soluble, potent curcumin analogue (CDF) to form nanomicelles (NM), HA-SMA-TPGS-CDF has demonstrated excellent nanoparticle characteristics for parenteral delivery...
April 17, 2018: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/29673760/tumor-suppressive-functions-of-4-mu-on-breast-cancer-cells-of-different-er-status-regulation-of-hyaluronan-has2-cd44-and-specific-matrix-effectors
#13
Theodoros T Karalis, Paraskevi Heldin, Demitrios H Vynios, Thomas Neill, Simone Buraschi, Renato V Iozzo, Nikos K Karamanos, Spyros S Skandalis
The malignant phenotype of various cancers is linked to enhanced expression of hyaluronan, a pro-angiogenic glycosaminoglycan whose expression is suppressed by 4-methylumbelliferone (4-MU), a non-toxic oral agent used as a dietary supplement to improve health and combat prostate cancer. However, little is known about the effects of hyaluronan inhibition by 4-MU on breast cancer cells. In this study, we investigated the role of 4-MU in mammary carcinoma cells with distinct malignant phenotypes and estrogen receptor (ER) status, a major prognostic factor in the clinical management of breast cancers...
April 16, 2018: Matrix Biology: Journal of the International Society for Matrix Biology
https://www.readbyqxmd.com/read/29666928/implications-of-esr1-mutations-in-hormone-receptor-positive-breast-cancer
#14
REVIEW
Tomás Reinert, Rodrigo Gonçalves, José Bines
Endocrine treatment resistance eventually develops during adjuvant and even more often during hormonal treatment for advanced breast cancer (ABC). An ESR1 gene mutation, which encodes for the estrogen receptor (ER) protein, is one of the potential mechanisms of therapy resistance. The ESR1 mutations result in conformational changes in the ER leading to subsequent estrogen-independent transcriptional activity. These mutations are found at a lower level in early stage when compared to metastatic BC, more often through selective pressure after aromatase inhibitor (AI) treatment...
April 17, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29622982/cardiovascular-disease-and-abo-blood-groups-in-africans-are-blood-group-a-individuals-at-higher-risk-of-ischemic-disease-a-pilot-study
#15
Djibril Marie Ba, Mamadou Saidou Sow, Aminata Diack, Khadidiatou Dia, Mouhamed Cherif Mboup, Pape Diadie Fall, Moussa Daouda Fall
Background: Since the discovery of the ABO blood group system by Karl Landsteiner in 1901, several reports have suggested an important involvement of the ABO blood group system in the susceptibility to thrombosis. Assessing that non-O blood groups in particular A blood group confer a higher risk of venous and arterial thrombosis than group O.Epidemiologic data are typically not available for all racial and ethnics groups.The purpose of this pilot study was to identify a link between ABO blood group and ischemic disease (ID) in Africans, and to analyze whether A blood group individuals were at higher risk of ischemic disease or not...
December 2017: The Egyptian heart journal: (EHJ): official bulletin of the Egyptian Society of Cardiology
https://www.readbyqxmd.com/read/29605636/rapid-effects-of-17%C3%AE-estradiol-on-aggressive-behavior-in-songbirds-environmental-and-genetic-influences
#16
REVIEW
Sarah A Heimovics, Jennifer R Merritt, Cecilia Jalabert, Chunqi Ma, Donna L Maney, Kiran K Soma
17β-estradiol (E2 ) has numerous rapid effects on the brain and behavior. This review focuses on the rapid effects of E2 on aggression, an important social behavior, in songbirds. First, we highlight the contributions of studies on song sparrows, which reveal that seasonal changes in the environment profoundly influence the capacity of E2 to rapidly alter aggressive behavior. E2 administration to male song sparrows increases aggression within 20 min in the non-breeding season, but not in the breeding season...
March 29, 2018: Hormones and Behavior
https://www.readbyqxmd.com/read/29575937/bp1-a-potential-biomarker-for-breast-cancer-prognosis
#17
Yaoxian Lou, Yassi Fallah, Kellie Yamane, Patricia E Berg
Homeobox genes are critical in tumor development. An isoform protein of DLX4 called BP1 is expressed in 80% of invasive ductal breast carcinomas. BP1 overexpression is implicated in an aggressive phenotype and poor prognosis. BP1 upregulation is associated with estrogen receptor negativity so those tumors do not respond to antiestrogens. Breast cancer is the second leading cause of death in women. BP1 could serve as both a novel prognostic biomarker for breast cancer and a therapeutic target. In this review, we address the role of BP1 protein in tumorigenesis of breast cancer and four other malignancies...
March 26, 2018: Biomarkers in Medicine
https://www.readbyqxmd.com/read/29573201/intake-of-bean-fiber-beans-and-grains-and-reduced-risk-of-hormone-receptor-negative-breast-cancer-the-san-francisco-bay-area-breast-cancer-study
#18
Meera Sangaramoorthy, Jocelyn Koo, Esther M John
High dietary fiber intake has been associated with reduced breast cancer risk, but few studies considered tumor subtypes defined by estrogen receptor (ER) and progesterone receptor (PR) status or included racial/ethnic minority populations who vary in their fiber intake. We analyzed food frequency data from a population-based case-control study, including 2135 breast cancer cases (1070 Hispanics, 493 African Americans, and 572 non-Hispanic Whites (NHWs)) and 2571 controls (1391 Hispanics, 557 African Americans, and 623 NHWs)...
March 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29567811/epigenome-wide-src-1-mediated-gene-silencing-represses-cellular-differentiation-in-advanced-breast-cancer
#19
Elspeth Ward, Damir Vareslija, Sara Charmsaz, Ailis Fagan, Alacoque L Browne, Nicola S Cosgrove, Sinead Cocchiglia, Siobhan P Purcell, Lance Hudson, Sudipto Das, Darran O'Connor, Phillip J O'Halloran, Andrew H Sims, Arnold D Hill, Leonie S Young
PURPOSE: Despite the clinical utility of endocrine therapies for estrogen receptor positive (ER) breast cancer, up to 40% of patients eventually develop resistance, leading to disease progression. The molecular determinants that drive this adaptation to treatment remain poorly understood. Methylome aberrations drive cancer growth yet the functional role and mechanism of these epimutations in drug resistance are poorly elucidated. EXPERIMENTAL DESIGN: Genome-wide multi-omics sequencing approach identified a differentially methylated hub of pro-differentiation genes in endocrine resistant breast cancer patients and cell models...
March 22, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29566609/dna-methylation-status-of-the-estrogen-receptor-%C3%AE-gene-in-canine-mammary-tumors
#20
Yara de Oliveira Brandão, Mariana Busato Toledo, Andressa Chequin, Thierry Grima Cristo, Renato Silva Sousa, Edneia Amancio Souza Ramos, Giseli Klassen
Estrogen receptor α (ERα) has an important role in mammary carcinogenesis, prognosis, and treatment. In human and canine mammary cancer, the most aggressive tumors show loss of ERα expression, which in human breast cancer has been attributed to methylation of the cytosine followed by guanine (CpG) island within the estrogen receptor α gene ( ESR1) promoter. This study aimed to investigate the role of ESR1 CpG island (CGI) methylation in ERα expression in canine mammary tumors. Twenty-one canine mammary samples were sorted into three groups: malignant tumor (n = 9), benign tumor (n = 8), and normal gland (n = 4)...
January 1, 2018: Veterinary Pathology
keyword
keyword
30210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"